Clinical Trial DRUG P3-STS-01
- A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
- Principal Investigator
- Mark Agulnik
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG P3-STS-01
- The purpose of this study is to see if aldoxorubicin (the study drug) will slow cancer growth and also to evaluate the side effects of the treatment. Aldoxorubicin is a pro-drug of an approved chemotherapy drug called doxorubicin. Pro-drugs are inactive forms of a drug that only become active once inside the body.
- This is a study of an investigational drug called aldoxorubicin. Investigational products have not received approval from regulatory authorities such as the United States Food and Drug Administration (FDA), which means they are still being studied to understand how safe they are and whether or not they are effective. The active part of aldoxorubicin is doxorubicin, a very powerful anti-tumor drug that is one of the most active anticancer drugs developed to date. It is used in the treatment of blood cancers and solid tumors such as breast and ovarian cancer. However, doxorubicin’s usefulness is limited by toxic dose-related side effects.
Some of the eligibility criteria include:
- Participants must have high-grade sarcoma that is locally advanced and/or metastatic (it has spread beyond the original tumor) and cannot be removed with surgery.
- Participants must be 15 or older.
- Participants must have disease that has either returned or not responded to one or more prior treatment regimens.
- Description of Treatment
- Participants is this study will be randomized to receive either aldoxorubicin or the study doctor’s choice of treatment. Those selected to receive aldoxorubicin will receive the drug IV (through a vein) once every 3 weeks (21 days) until the tumor progresses. This 3 week (21 day) period is called a cycle. Those selected to receive the standard treatment of the doctor’s choice will have cycles that usually last up to 28 days. The doctor will discuss this choice with each participant in greater detail, including the length of a cycle.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Mark Agulnik
- TPF Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized Phase 2 Study in Patients w/ Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
- A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
- A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
- Phase I/II trial of Cediranib alone or Cediranib and Lenalidomide in iodine 131-refractory differentiated thyroid cancer
- Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (OER-SAR-043)
- A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
- A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing–Like Sarcomas
- Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
last updated: 22-Oct-14 11:26 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.